Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trials Disclosure Code From International Group Covers All Studies Of Life-Threatening Conditions

This article was originally published in The Pink Sheet Daily

Executive Summary

IFPMA says policy covers early stage safety trials -- a subset not mentioned in PhRMA's Clinical Trial Code.

You may also be interested in...



Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak

As Big Pharma companies back away from developing primary care products because of rising development costs and regulatory risk, they are increasingly turning to specialty medicines to fill their pipeline holes. One therapeutic area of particular interest: the inflammation/auto-immune space

Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak

As Big Pharma companies back away from developing primary care products because of rising development costs and regulatory risk, they are increasingly turning to specialty medicines to fill their pipeline holes. One therapeutic area of particular interest: the inflammation/auto-immune space

PhRMA Clinical Trial Code: Disclosure Edition

PhRMA is using broad disclosure as a defense against questions of clinical trial bias. Disclosure used to be a penalty forced on firms in consent decrees and lawsuits; now it appears as a pillar to building trust for corporate-sponsored trials.

Related Content

Topics

UsernamePublicRestriction

Register

PS068726

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel